Man Group’s Beta Bionics BBNX Stock Holding History

Man Group’s Portfolio BBNX Stock Details BBNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$393K	Buy	39,267 +27,946	+247%	+$413K	﹤0.01%	2140
2025 Q4	$345K	Buy	+11,321	New	+$302K	﹤0.01%	1984

Other funds holding BBNX

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Man Group's BBNX Position: Q1 2026 in Review

Man Group increased its Beta Bionics (BBNX) stake by 247% in Q1 2026, buying an estimated $413K and bringing the position to 39,267 shares worth $393K. The position accounts for ﹤0.01% of the portfolio, ranked #2140.

Man Group first reported a position in BBNX in Q4 2025 and has held it in 2 quarters since. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

Man Group held 39,267 shares of Beta Bionics worth $393K as of Q1 2026.
Man Group bought 27,946 Beta Bionics shares in Q1 2026, an estimated $413K.
Beta Bionics made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #2140 holding.
Man Group first reported a position in Beta Bionics in Q4 2025 and has held it in 2 quarters since.
130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.